OLUFUNKE OLUDIPE: Open Payments
NPI 1134902075 · SOUTHLAKE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,872 in 160 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $2,872
Food & beverage: $2,872
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $350 |
| Janssen Pharmaceuticals, Inc | 23 | $312 |
| E.R. Squibb & Sons, L.L.C. | 16 | $265 |
| Teva Pharmaceuticals USA, Inc. | 13 | $250 |
| Otsuka America Pharmaceutical, Inc. | 14 | $241 |
| ABBVIE INC. | 15 | $221 |
| Axsome Therapeutics, Inc. | 12 | $211 |
| Corium, LLC | 10 | $208 |
| Neurocrine BioSciences, Inc. | 6 | $155 |
| Lundbeck LLC | 10 | $147 |
Products named: CAPLYTA, REXULTI, COBENFY, VRAYLAR, Auvelity, Azstarys, SPRAVATO, INGREZZA.
Industry payments across TX — which companies pay providers there.
